Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2016

25.08.2016 | Original Article – Cancer Research

MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells

verfasst von: Kati Erdmann, Knut Kaulke, Christiane Rieger, Karsten Salomo, Manfred P. Wirth, Susanne Fuessel

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The tumor-suppressive microRNAs miR-26a and miR-138 are significantly down-regulated in prostate cancer (PCa) and have been identified as direct regulators of enhancer of zeste homolog 2 (EZH2), which is a known oncogene in PCa. In the present study, the influence of miR-26a and miR-138 on EZH2 and cellular function including the impact on the cell cycle regulating network was evaluated in PCa cells.

Methods

PC-3 and DU-145 PCa cells were transfected with 100 nM of miRNA mimics, siRNA against EZH2 (siR-EZH2) or control constructs for 4 h. Analyses of gene expression and cellular function were conducted 48 h after transfection.

Results

Both miRNAs influenced the EZH2 expression and activity only marginally, whereas siR-EZH2 led to a notable decrease of the EZH2 expression and activity. Both miRNAs inhibited short- and/or long-term proliferation of PCa cells but showed no effect on viability and apoptosis. In PC-3 cells, miR-26a and miR-138 caused a significant surplus of cells in the G0/G1 phase of 6 and 12 %, respectively, thus blocking the G1/S-phase transition. Treatment with siR-EZH2 was without substantial influence on cellular function and cell cycle. Therefore, alternative target genes involved in cell cycle regulation were identified in silico. MiR-26a significantly diminished the expression of its targets CCNE1, CCNE2 and CDK6, whereas CCND1, CCND3 and CDK6 were suppressed by their regulator miR-138.

Conclusions

The present findings suggest an anti-proliferative role for miR-26a and miR-138 in PCa by blocking the G1/S-phase transition independent of EZH2 but via a concerted inhibition of crucial cell cycle regulators.
Literatur
Zurück zum Zitat Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O’Sullivan B, Liu FF (2010) Enhancer of zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis 1:e85. doi:10.1038/cddis.2010.64 PubMedPubMedCentral Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O’Sullivan B, Liu FF (2010) Enhancer of zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis 1:e85. doi:10.​1038/​cddis.​2010.​64 PubMedPubMedCentral
Zurück zum Zitat Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, Perou CM, Liu H (2014) Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res 74:7406–7417. doi:10.1158/0008-5472.CAN-14-1188 PubMedPubMedCentral Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, Perou CM, Liu H (2014) Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res 74:7406–7417. doi:10.​1158/​0008-5472.​CAN-14-1188 PubMedPubMedCentral
Zurück zum Zitat Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Rohr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sultmann H, Lehrach H, Schweiger MR (2012) Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2:1024–1035. doi:10.1158/2159-8290.CD-12-0041 PubMed Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Rohr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sultmann H, Lehrach H, Schweiger MR (2012) Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2:1024–1035. doi:10.​1158/​2159-8290.​CD-12-0041 PubMed
Zurück zum Zitat Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547–556PubMed Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547–556PubMed
Zurück zum Zitat Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y (2012) MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 205:113–123PubMed Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y (2012) MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 205:113–123PubMed
Zurück zum Zitat Erdmann K, Ringel J, Hampel S, Rieger C, Huebner D, Wirth MP, Fuessel S (2014b) Chemosensitizing effects of carbon-based nanomaterials in cancer cells: enhanced apoptosis and inhibition of proliferation as underlying mechanisms. Nanotechnology 25:405102. doi:10.1088/0957-4484/25/40/405102 PubMed Erdmann K, Ringel J, Hampel S, Rieger C, Huebner D, Wirth MP, Fuessel S (2014b) Chemosensitizing effects of carbon-based nanomaterials in cancer cells: enhanced apoptosis and inhibition of proliferation as underlying mechanisms. Nanotechnology 25:405102. doi:10.​1088/​0957-4484/​25/​40/​405102 PubMed
Zurück zum Zitat Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, Lou G, Wang X, Lou F, Yen Y, Yu H, Jove R, Huang W (2014) miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene 33:4296–4306. doi:10.1038/onc.2013.385 PubMed Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, Lou G, Wang X, Lou F, Yen Y, Yu H, Jove R, Huang W (2014) miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene 33:4296–4306. doi:10.​1038/​onc.​2013.​385 PubMed
Zurück zum Zitat Han LP, Fu T, Lin Y, Miao JL, Jiang QF (2015) MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3. Tumour Biol. doi:10.1007/s13277-015-3757-8 Han LP, Fu T, Lin Y, Miao JL, Jiang QF (2015) MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3. Tumour Biol. doi:10.​1007/​s13277-015-3757-8
Zurück zum Zitat Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23:1327–1337PubMedPubMedCentral Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23:1327–1337PubMedPubMedCentral
Zurück zum Zitat Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodriguez-Gonzalez FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM (2012) High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat 133:937–947. doi:10.1007/s10549-011-1877-4 PubMed Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodriguez-Gonzalez FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM (2012) High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat 133:937–947. doi:10.​1007/​s10549-011-1877-4 PubMed
Zurück zum Zitat Kisliouk T, Yosefi S, Meiri N (2011) MiR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition. Eur J Neurosci 33:224–235PubMed Kisliouk T, Yosefi S, Meiri N (2011) MiR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition. Eur J Neurosci 33:224–235PubMed
Zurück zum Zitat Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM (2011) Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2:669–683PubMedPubMedCentral Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM (2011) Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2:669–683PubMedPubMedCentral
Zurück zum Zitat Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017PubMedPubMedCentral Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017PubMedPubMedCentral
Zurück zum Zitat Li X, Liu L, Shen Y, Wang T, Chen L, Xu D, Wen F (2014) MicroRNA-26a modulates transforming growth factor beta-1-induced proliferation in human fetal lung fibroblasts. Biochem Biophys Res Commun 454:512–517. doi:10.1016/j.bbrc.2014.10.106 PubMed Li X, Liu L, Shen Y, Wang T, Chen L, Xu D, Wen F (2014) MicroRNA-26a modulates transforming growth factor beta-1-induced proliferation in human fetal lung fibroblasts. Biochem Biophys Res Commun 454:512–517. doi:10.​1016/​j.​bbrc.​2014.​10.​106 PubMed
Zurück zum Zitat Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, Chen Z, Zhao J (2013) MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res 21:83–91. doi:10.3727/096504013X13775486749218 PubMed Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, Chen Z, Zhao J (2013) MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res 21:83–91. doi:10.​3727/​096504013X137754​86749218 PubMed
Zurück zum Zitat Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, Dai Y, Zhou X (2011) MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 440:23–31PubMedPubMedCentral Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, Dai Y, Zhou X (2011) MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 440:23–31PubMedPubMedCentral
Zurück zum Zitat Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K, Wu M, Liang Y, Liu P, Tang J, Lu WH, Feng QS, Chen LZ, Qian CN, Bei JX, Kang T, Zeng YX (2012b) MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle 11:2495–2506PubMed Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K, Wu M, Liang Y, Liu P, Tang J, Lu WH, Feng QS, Chen LZ, Qian CN, Bei JX, Kang T, Zeng YX (2012b) MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle 11:2495–2506PubMed
Zurück zum Zitat Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP (2011) MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71:225–233PubMed Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP (2011) MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71:225–233PubMed
Zurück zum Zitat Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, Cao MQ, Gao DM, Sun HC, Tang ZY (2016) MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. J Hematol Oncol 9:1. doi:10.1186/s13045-015-0229-y PubMedPubMedCentral Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, Cao MQ, Gao DM, Sun HC, Tang ZY (2016) MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. J Hematol Oncol 9:1. doi:10.​1186/​s13045-015-0229-y PubMedPubMedCentral
Zurück zum Zitat Qiu S, Huang D, Yin D, Li F, Li X, Kung HF, Peng Y (2013) Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta 1832:1697–1707. doi:10.1016/j.bbadis.2013.05.015 PubMed Qiu S, Huang D, Yin D, Li F, Li X, Kung HF, Peng Y (2013) Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta 1832:1697–1707. doi:10.​1016/​j.​bbadis.​2013.​05.​015 PubMed
Zurück zum Zitat Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Moller P, Stilgenbauer S, Pollack JR, Wirth T (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112:4202–4212PubMed Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Moller P, Stilgenbauer S, Pollack JR, Wirth T (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112:4202–4212PubMed
Zurück zum Zitat Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T (2006) The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45:639–645. doi:10.1002/gcc.20327 PubMed Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T (2006) The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45:639–645. doi:10.​1002/​gcc.​20327 PubMed
Zurück zum Zitat Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A (2006) Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 66:1521–1534PubMed Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A (2006) Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 66:1521–1534PubMed
Zurück zum Zitat Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D, Wang L, Wang YJ, Zong Y, Wu YD, Zhang ST (2016) MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget 7:15173–15186. doi:10.18632/oncotarget.7908 PubMedPubMedCentral Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D, Wang L, Wang YJ, Zong Y, Wu YD, Zhang ST (2016) MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget 7:15173–15186. doi:10.​18632/​oncotarget.​7908 PubMedPubMedCentral
Zurück zum Zitat Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29PubMed Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29PubMed
Zurück zum Zitat Song QC, Shi ZB, Zhang YT, Ji L, Wang KZ, Duan DP, Dang XQ (2014) Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients. Oncol Rep 31:1263–1270. doi:10.3892/or.2014.2989 PubMed Song QC, Shi ZB, Zhang YT, Ji L, Wang KZ, Duan DP, Dang XQ (2014) Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients. Oncol Rep 31:1263–1270. doi:10.​3892/​or.​2014.​2989 PubMed
Zurück zum Zitat Sun TY, Xie HJ, He H, Li Z, Kong LF (2016) miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res 8:1037–1046PubMedPubMedCentral Sun TY, Xie HJ, He H, Li Z, Kong LF (2016) miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res 8:1037–1046PubMedPubMedCentral
Zurück zum Zitat Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629PubMed Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629PubMed
Zurück zum Zitat Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT (2012) MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33:1113–1120PubMedPubMedCentral Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT (2012) MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33:1113–1120PubMedPubMedCentral
Zurück zum Zitat Wong CF, Tellam RL (2008) MicroRNA-26a targets the histone methyltransferase enhancer of zeste homolog 2 during myogenesis. J Biol Chem 283:9836–9843PubMed Wong CF, Tellam RL (2008) MicroRNA-26a targets the histone methyltransferase enhancer of zeste homolog 2 during myogenesis. J Biol Chem 283:9836–9843PubMed
Zurück zum Zitat Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37:D105–D110. doi:10.1093/nar/gkn851 PubMed Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37:D105–D110. doi:10.​1093/​nar/​gkn851 PubMed
Zurück zum Zitat Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338:1465–1469. doi:10.1126/science.1227604 PubMedPubMedCentral Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338:1465–1469. doi:10.​1126/​science.​1227604 PubMedPubMedCentral
Zurück zum Zitat Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y, Chim CS, Zheng X, Yu L (2014) BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene 33:44–54. doi:10.1038/onc.2012.557 PubMed Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y, Chim CS, Zheng X, Yu L (2014) BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene 33:44–54. doi:10.​1038/​onc.​2012.​557 PubMed
Zurück zum Zitat Zeitels LR, Acharya A, Shi G, Chivukula D, Chivukula RR, Anandam JL, Abdelnaby AA, Balch GC, Mansour JC, Yopp AC, Richardson JA, Mendell JT (2014) Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis. Genes Dev 28:2585–2590. doi:10.1101/gad.250951.114 PubMedPubMedCentral Zeitels LR, Acharya A, Shi G, Chivukula D, Chivukula RR, Anandam JL, Abdelnaby AA, Balch GC, Mansour JC, Yopp AC, Richardson JA, Mendell JT (2014) Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis. Genes Dev 28:2585–2590. doi:10.​1101/​gad.​250951.​114 PubMedPubMedCentral
Zurück zum Zitat Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q (2011) Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32:2–9. doi:10.1093/carcin/bgq209 PubMed Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q (2011) Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32:2–9. doi:10.​1093/​carcin/​bgq209 PubMed
Zurück zum Zitat Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, Liu H, Du W, Zhou W, Chen X, Fei K (2013) MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 31:56–65. doi:10.1159/000343349 PubMed Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, Liu H, Du W, Zhou W, Chen X, Fei K (2013) MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 31:56–65. doi:10.​1159/​000343349 PubMed
Zurück zum Zitat Zhang X, Xiao D, Wang Z, Zou Y, Huang L, Lin W, Deng Q, Pan H, Zhou J, Liang C, He J (2014) MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer. Mol Cancer Res 12:1535–1546. doi:10.1158/1541-7786.MCR-13-0641 PubMed Zhang X, Xiao D, Wang Z, Zou Y, Huang L, Lin W, Deng Q, Pan H, Zhou J, Liang C, He J (2014) MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer. Mol Cancer Res 12:1535–1546. doi:10.​1158/​1541-7786.​MCR-13-0641 PubMed
Zurück zum Zitat Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM (2012) MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40:4615–4625PubMed Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM (2012) MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40:4615–4625PubMed
Metadaten
Titel
MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells
verfasst von
Kati Erdmann
Knut Kaulke
Christiane Rieger
Karsten Salomo
Manfred P. Wirth
Susanne Fuessel
Publikationsdatum
25.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2222-4

Weitere Artikel der Ausgabe 11/2016

Journal of Cancer Research and Clinical Oncology 11/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.